文献速递胸部肿瘤

ASCEND-8:色瑞替尼450mg或600mg随低脂餐与750mg空腹给药对比的随机1期研究,用于间变性淋巴瘤激酶(ALK)重排转移性非小细胞肺癌患者

ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC).
PubMed 文献 · J Thorac Oncol · 2017-07-17

ASCEND-8为多中心、随机、开放标签1期研究第1部分,比较色瑞替尼450mg或600mg随低脂餐与750mg空腹给药在晚期ALK阳性NSCLC患者中的稳态药代动力学与安全性。截至2016年6月16日共随机137例(450mg随餐44例、600mg随餐47例、750mg空腹46例),135例接受治疗,中位随访4.14个月。结果显示450mg随餐与750mg空腹暴露相当,且胃肠道毒性比例更低。

要点

  • 450mg随餐与750mg空腹稳态暴露相当,600mg随餐暴露约高25%。
  • 450mg随餐组胃肠道毒性比例低于750mg空腹组,多为1级。
  • 450mg随餐组未发生因胃肠道毒性导致的3或4级事件、停药或严重不良事件。

核心结论

  • 色瑞替尼450mg随餐给药与750mg空腹给药暴露相似,且胃肠道安全性特征更有利。

研究设计与样本

  • 多中心、随机、开放标签1期研究;第1部分评估稳态药代动力学与安全性,第2部分将评估初治患者的疗效与安全性。
  • 截至2016年6月16日随机137例:450mg随餐44例、600mg随餐47例、750mg空腹46例;135例接受色瑞替尼治疗。
  • 入组为晚期ALK阳性NSCLC患者,可为初治或曾接受化疗和/或克唑替尼治疗。
  • 中位随访时间4.14个月。

主要发现

  • 稳态时,相对750mg空腹,450mg随餐的最大(峰值)血浆药物浓度与0至24小时血浆浓度-时间曲线下面积相当。
  • 稳态时,相对750mg空腹,600mg随餐的药代动力学暴露约高25%。
  • 相对750mg空腹,450mg随餐组发生胃肠道毒性的患者比例更低,多为1级:腹泻43.2%、恶心29.5%、呕吐18.2%。
  • 450mg随餐组无3或4级事件、无研究药物停药、无因胃肠道毒性的严重不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Ceritinib, 750 mg fasted, is approved for treatment of patients with ALK receptor tyrosine kinase gene (ALK)-rearranged (ALK-positive) NSCLC previously treated with crizotinib. Part 1 of the ASCEND-8 study determined whether administering ceritinib, 450 mg or 600 mg, with a low-fat meal may enhance gastrointestinal (GI) tolerability versus 750 mg fasted in patients with ALK-positive NSCLC while maintaining similar exposure. METHODS: ASCEND-8 is a multicenter, randomized, open-label, phase 1 study. Part 1 investigated the steady-state pharmacokinetics (PK) and safety of ceritinib, 450 mg or 600 mg, taken with a low-fat meal versus 750 mg fasted in patients with advanced ALK-positive NSCLC who were either treatment naive or pretreated with chemotherapy and/or crizotinib. Part 2 will assess efficacy and safety of ceritinib in treatment-naive patients. RESULTS: As of June 16, 2016, 137 patients were randomized (450 mg fed [n = 44], 600 mg fed [n = 47], and 750 mg fasted [n = 46]); 135 patients received ceritinib. Median follow-up duration was 4.14 months. At steady state, relative to 750 mg fasted, 450 mg with food demonstrated comparable PK as assessed by maximum (peak) concentration of drug in plasma and area under the plasma concentration-time curve from time zero to 24 hours, whereas 600 mg with food demonstrated approximately 25% higher PK. Relative to 750 mg fasted, 450 mg with food was associated with a lower proportion of patients with GI toxicities, mostly grade 1 (diarrhea [43.2%], nausea [29.5%], and vomiting [18.2%]); there were no grade 3 or 4 events, study drug discontinuations, or serious AEs due to GI toxicities. CONCLUSION: Ceritinib, 450 mg with food, had similar exposure and a more favorable GI safety profile than ceritinib, 750 mg in fasted patients with ALK-positive NSCLC.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Cho BC, Kim DW, Bearz A, et al. ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol. 2017. PMID: 28729021. doi:10.1016/j.jtho.2017.07.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。